2021 CMSC Annual Meeting

Tag: MD2

Poster-Neuroimmunology and disease models

Mucosal Associated Invariant T (MAIT) Cells Show Defective Activation in People with Multiple Sclerosis

Background: mucosal associated invariant T (MAIT) cells are innate-like T cells expressing an invariant TCR ? chain with a limited number...

Read More

Poster-Non-imaging Biomarkers

Cerebrospinal Fluid Protein Is Higher in Males with Multiple Sclerosis: Results from an International Multicenter Cohort

Background: Sex has a differential effect on MS disease severity. Males tend to have a more severe clinical course and a greater tendency...

Read More

Poster-Multidisciplinary Care

National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis

Background: Historically, multiple sclerosis (MS) has been underdiagnosed among African Americans with MS (AAwMS). Recent evidence suggests...

Read More

Poster-Disease-modifying Therapy

Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis

INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...

Read More

Poster-Imaging

Importance of Cervical Magnetic Resonance Imaging in the Diagnosis, Treatment, and Monitoring of Hispanic Puerto Rican Multiple Sclerosis Patients

Background: Some Health Insurances in Puerto Rico (PR) limit the number of magnetic resonance imaging (MRI) procedures that can be done in...

Read More

Poster-Disease-modifying Therapy

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...

Read More

Poster-Disease-modifying Therapy

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...

Read More

Poster-Disease-modifying Therapy

Safety of Eculizumab in Nmosd and MG – Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions

Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...

Read More

Poster-Disease-modifying Therapy

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More